RNS Number: 9837 C Indivior PLC 14 February 2020 TR-1: S tandard form for notification of major holdings. i Please note that national forms may vary due to specific national legislation as for instance the applicable thresholds or information regarding capital holdings.. Indicate in the relevant section whether the issuer is a non UK issuer..
RNS Number: 9085 C Indivior PLC 13 February 2020 Indivior PLC- Board Committee Changes. Slough, UK and Richmond, VA, February 13, 2020- Indivior PLC announces that Daniel Tass é will step down as Chair of the Audit Committee and Graham Hetherington will take on the role of Chair of that Committee. RNS is approved by the Financial Conduct Authority to act as a Primary...
RNS Number: 8384 C Indivior PLC 13 February 2020 pdf. FY 2019 Adjusted Financial Results In-Line with Guidance. Supported by our enhanced compliance capabilities to meet the growing number of buprenorphine medication-assisted treatment patients and prescribers, we expect these...
RNS Number: 7514 B Indivior PLC 03 February 2020 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at February 1, 2020 the Company's issued share capital consisted of 731,716,604 O rdinary Shares of US $0.10 each. RNS is approved by the...
RNS Number: 3425 B Indivior PLC 29 January 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Slough, UK, and Richmond, VA, January 13, 2020- Indivior PLC today announced that it will release its FY 2019 results on February 13th at 7:00 a.m. London time. Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will present the FY 2019 results and address questions from qualified analysts and investors at 11:30 a.m. London...
RNS Number: 1873 X Indivior PLC 02 January 2020 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at January 1, 2020 the Company's issued share capital consisted of 730,787,719 O rdinary Shares of US $0.10 each. RNS is approved by the...
RNS Number: 4684 Y Indivior PLC 02 January 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5534 W Indivior PLC 11 December 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4279 W Indivior PLC 11 December 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4012 W Indivior PLC 10 December 2019 Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder. Slough, UK and Richmond, VA, 10 December 2019- Indivior PLC today announced a new research collaboration with Virginia Tech extending the RECOVER Study™. "The Virginia Tech-Indivior study is a...
RNS Number: 3357 W Indivior PLC 10 December 2019 Indivior PLC- Block listing of shares. Application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 5,000,000 Ordinary Shares of US$ 0.10 each to trade on the London Stock Exchange and to be admitted to the Official List. RNS is approved by the Financial Conduct Authority...
RNS Number: 2161 W Indivior PLC 09 December 2019 Indivior PLC- Board Committee Changes. Slough, UK and Richmond, VA, December 9, 2019- Indivior PLC announces that Tom McLellan will step down as Chair of the Science& Policy Committee and Peter Bains will take on the role of Chair of that Committee. RNS is approved by the Financial Conduct Authority to act as a Primary...
RNS Number: 3053 V Indivior PLC 02 December 2019 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at December 1, 2019 the Company's issued share capital consisted of 730,765,489 O rdinary Shares of US $0.10 each. RNS is approved by the...
RNS Number: 2352 V Indivior PLC 02 December 2019 New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes. -Sustained improvements in multiple health outcomes following twelve monthly buprenorphine extended-release injections in patients with opioid use disorder-.
RNS Number: 0410 T Indivior PLC 12 November 2019 Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder and to Let People with OUD Know That They Can "Keep Moving Towards Recovery". -Only 20% of people suffering from the disease receive any kind of treatment-. Richmond, VA, November 12, 2019- Indivior PLC announces...
RNS Number: 9465 S Indivior PLC 11 November 2019 BLOCK LISTING SIX MONTHLY RETURN. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5382 S Indivior PLC 06 November 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2085 S Indivior PLC 04 November 2019. Indivior to Participate in Upcoming Investor Conferences. Slough, UK, and Richmond, VA- 4 November 2019- Indivior PLC today announced that it will participate in the following Investor Conferences the week of November 18th.
Bid
--
-
Ask
- High-
- OPEN-
- VOL-
- MKT CAP-m
- LOW-
- CLOSE-
- AVG VOL-
- SHARES IN ISSUE730.03M
Company Profile
Indivior is a pharmaceutical company specialising in addiction treatment. Indivior was spun out of parent Reckitt Benckiser in December 2014. Adding to its Suboxone opioid addiction product, the company has a pipeline including longer-lasting 'depot' formulations, treatments for cocaine intoxication, alcohol addiction and even schizophrenia, as a psychiatric co-morbidity of addiction.
Classification
| Market Indices | - |
Locations
| HQ | 103-105 Bath Road Slough SL1 3UH |